双鹭药业：公司GLP-1长效制剂没有专利问题

Group 1 - The core issue raised by investors concerns the patent status of Dulaglutide and the delay in its submission for approval [2] - The company, Donglu Pharmaceutical, clarified on September 1 that there are no patent issues with its GLP-1 long-acting formulation and that it is currently preparing the necessary documentation for submission [2] - The specific timeline for the submission remains uncertain as the company is still in the process of gathering materials [2]